$NVCR

Ocean Allyson J sold $46K of NVCR

Ocean Allyson J sold 2,945 shares of NovoCure Ltd (NVCR) at $15.77 on 2026-06-02.

Original reporting
SEC EDGAR · Ocean Allyson J
Published Jun 3, 2026, 8:53 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NVCR
Neutral
medium confidence
Mentioned
$NVCR
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVCRNeutralLow
01

Why it matters

This provides a datapoint on director-level selling but does not include any operational or clinical update.

02

Market read

Traders may briefly reassess sentiment around NVCR, but the disclosure alone is unlikely to drive a durable repricing.

03

What to watch

The filing does not state reasons for sale; also, Form 4 timing can lag actual trades and may not reflect new information.

Relevance 5/10Novelty 3/10Timing: after-hours/next-session read-through from a just-filed Form 4

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for NovoCure, filed the same day as the sale date.

Company-level read

Ticker impact

$NVCRNeutralMedium confidence
Context

NovoCure director Ocean Allyson J sold 2,945 shares in an open-market transaction for about $46.4K, disclosed via SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless followed by additional disclosures or fundamental catalysts.

Evidence & confidence

The filing is an ownership-change disclosure with a small dollar amount and no stated linkage to earnings, trials, or guidance.

Market effects

Limited read-across to biotech/oncology peers; insider Form 4s are common and typically low signal absent pattern or material size.

None.

None.

Counterpoint

A non-10b5-1 sale can be routine liquidity/portfolio rebalancing; the small size suggests no major conviction shift.

Key entities

  • NovoCure Ltd

    Company whose director sold shares; subject of the SEC Form 4 disclosure.

  • Ocean Allyson J

    Director who executed an open-market sale of 2,945 NVCR shares.

Related articles

$CSXMedAI 8/10

Why Did CSX, UNP, NVCR Stocks Surge To 52-Week Highs Today?

CSX, Union Pacific (UNP), and Novocure (NVCR) reached 52-week highs after Q2 results beat analyst expectations. CSX reported $3.94B revenue and $0.54 EPS vs $3.8B and $0.52, and analysts raised targets. UNP posted $3.41 adjusted EPS and $6.9B revenue vs $3.23 and higher volumes. NVCR shares rose 28% after Q2 revenue rose 15.6% to $183.6M and adjusted EBITDA turned profitable.

$ADVBMed

Top Biotech Gainers: ADVB Soars Over 200% In A Week, NVCR, MEDP Report Q2 Results, AGMB In Focus

Biotech gainers highlighted include Advanced Biomed (ADVB), up about 211% this week to $16.78, with no product sales and a recent SEC registration withdrawal. Novocure (NVCR) rose over 28% after Q2 results and raised 2026 revenue guidance to $710M-$725M. Medpace (MEDP) gained 14% on Q2 revenue of $707.3M and 2026 outlook. SciSparc (SPRC) and Agenus (AGEN) also rose; AgomAb (AGMB) gained on upcoming trial readouts.